Roche Reveals Impact Of Multisource Biosimilar Competition
Avastin, Rituxan and Herceptin All Face Challengers
With biosimilars to Avastin on the way later this year in Europe, Roche will face competition to its three key biosimilar monoclonal antibodies in the US, EU and Japan. Management detailed to investors the company’s latest expectations.
You may also be interested in...
Merck & Co has launched Ontruzant, the trastuzumab biosimilar developed and manufactured by Samsung Bioepis, in the US following a staggered approval process and earlier intellectual-property hurdles. The list price discount offered by the firm puts it in the middle of the pack among the four other biosimilar players currently on the market.
Pfizer has launched its Ruxience rituximab biosimilar in the US at a 24% discount to the wholesale acquisition cost of the Rituxan original. The firm has also revealed that when it launches its Trazimera trastuzumab biosimilar in mid-February, it will be at a 22% discount to the Herceptin brand’s WAC.
Pfizer is getting ready to ship its Zirabev biosimilar rival to Avastin in the US, at a price that represents a 23% discount to the brand and is also lower than the price for Amgen’s Mvasi biosimilar.